Stress echocardiography causes stress cardiomyopathy: A very rare complication should be reminded

Do butamine stress echocardiography (DSE) is widely used for detection and risk stratification of patients with coronary artery diseases [1]. Recent advances both in stress protocol and digital imaging allow us more accurate assessment using DSE [2]. Dobutamine stress has been regarded as safe with few adverse events. Geleijnse reported major complications of dobutamine–atropine stress echocardiography in 116 patients or 0.2% among 55,071 patients [3]. The most common arrhythmic complication is atrial fibrillation. In a recent large cohort with 11,806 patients, 0.5% of patients developed atrial fibrillation which terminated within a day in most of the cases without serious cardiac events [4]. Even though the incidence is not frequent, complications may result in a serious morbidity or mortality. The most life-threatening complication of DSE is ventricular tachycardia which occurred in 0.15% of patients.

The present article written by Ho et al. [5] reported a case of Takotsubo cardiomyopathy (TCM) following DSE. TCM or transient apical ballooning is known as a stress-induced acute myopathy which is most likely to affect elder female patients as in the present case [6]. Psychiatric as well as physical stresses are the cause of TCM. Medical or dental procedures can also trigger this syndrome [7]. TCM mimics the symptoms and STT findings of ST elevation acute myocardial infarction. Compared to anterior acute myocardial infarction, TCM is associated with ST depression in aVR lead and lack of ST elevation in V1 lead [8]. Even though, the difference in the distribution of ST elevation, the most specific finding of TCM is the wall motion abnormality without coronary stenosis. About 80% of TCM develops apical ballooning with hyperkinetic motion of basal walls. However, several patterns of wall motion abnormality can be seen in TCM, such as biventricular, midventricular, and basal wall of left ventricle [9].

Several cases with TCM following DSE have already been reported (Table 1) [5,10–13]. All of the cases were elder females. Most of the patients developed TCM during the peak dobutamine at a standard dose, with or without atropine. Management of TCM is rather supportive when the hemodynamics show stability. Beta blockers could be considered if left ventricular outflow obstruction occurs. However, physicians should be cautious about the possibility of multivessel spasm before starting beta blockers in Japanese patients.

It is known that catecholamine levels are elevated in patients with TCM, suggesting increased synthesis or reuptake and decreased removal of catecholamines [14]. However, it is not certain that exogenous catecholamine infusion causes TCM. A clue might be in the fact that some patients developed TCM at the recovery period of DSE despite showing normal wall motion during peak stress such as in the present case [15]. It is also known that neuropsychiatric complications can be seen following DSE. Neuropsychiatric symptoms include confusion, memory disturbance, and disorientation, which occurred in 7.1% of patients within 24 h after DSE [16]. Not the dose of dobutamine but atropine use was the strongest predictor of neuropsychiatric symptoms. Underlying neuropsychiatric disease was also a predictor of these complications after DSE. These results suggested that patient’s anxiety and agony during DSE might be a trigger of neuropsychiatric reaction following DSE.

What should we do to avoid TCM following DSE? Probably we should pay much attention to choose the stress methods and protocol after assessing the patient’s characteristics, especially in the case of elderly ladies. We should also take much care of patients who demonstrate anxiety or agony during DSE by gentle explanation. Moreover, we should remind ourselves of the possibility of TCM even during the recovery period after DSE.

| Table 1 |
|Reported cases of takotsubo cardiomyopathy following DOB stress.|
|---|
|Author | Year | Age | Gender | Peak DOB | Atropine | Phase |
|Silberbauer | 2008 | 75 | Female | 30 | 0.5 mg | Peak |
|Cherian | 2008 | 85 | Female | 40 | No | Peak |
|Margery | 2009 | 61 | Female | 40 | No | Peak |
|Mosley | 2010 | 50 | Female | 30 | 0.5 mg | Peak |
| | 74 | Female | 40 | 0.25 mg | Peak |
|Shah | 2011 | 85 | Female | 30 | No | Recovery |
|Ho | 2012 | 83 | Female | 40 | 0.5 mg | Recovery |

DOB, dobutamine (mcg/kg/min).
References

[1] American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine; Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, Douglas PS, Garcia MJ, Haines DE, Lai WW, Manning WJ, Patel AR, et al. ACCF/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, Heart Failure Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. American College of Cardiology Foundation Appropriate Use Criteria Task Force; American Society of Echocardiography; American Heart Association; American Society of Nuclear Cardiology; Heart Failure Society of America; Heart Rhythm Society; Society for Cardiovascular Angiography and Interventions; Society of Critical Care Medicine; Society of Cardiovascular Computed Tomography; Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. J Am Coll Cardiol 2011;57:1265–66.

[2] Cullen MW, Pellilla PA. Recent advances in stress echocardiography. Curr Opin Cardiol 2011;26:379–84.

[3] Geleijnse ML, Krenning BJ, Nemes A, van Dalen BM, Soliman OLL, ten Cate FJ, Schinkel AFL, Boersma E, Simoons ML. Incidence, pathophysiology, and treatment of complications during dobutamine-atropine stress echocardiography. Circulation 2010;121:1756–67.

[4] Sheldon SH, Askew JW, Klarich RS, Patel AR, McCully RB. Occurrence of atrial fibrillation during dobutamine stress echocardiography: incidence, risk factors, and outcomes. J Am Soc Echocardiogr 2011;24:86–90.

[5] Ho J, Rahl R, Cannaday J, Patel R, Engstrom A, Henderson Y, Ramsay M. Takotsubo cardiomyopathy occurring during the recovery period of dobutamine stress echocardiography. J Cardiol Case 2012;5:e155–9.

[6] Bybee KA, Kara T, Prasad A, Leman A, Barsness GW, Wright RS, Rihal CS. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med 2004;141:858–65.

[7] Tsuchihashi K, Ueshima K, Uchida T, Oh-mura N, Kimura K, Owa M, Yoshiyama M, Miyazaki S, Haze K, Ogawa H, Honda T, Hase M, Kai R, Morii I. Transient left ventricular apical ballooning without coronary artery stenosis: a novel heart syndrome mimicking acute myocardial infarction. J Am Coll Cardiol 2001;38:11–8.

[8] Kosuge M, Ebina T, Hibi K, Morita S, Okuda J, Iwahashi N, Tsukahara K, Nakachi T, Kiyokuni M, Ishikawa T, Umemura S, Kimura K. Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction. J Am Coll Cardiol 2010;55:2514–7.

[9] Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, Francone M, Desch S, Gutterer M, Strohm O, Schuler G, Schulz-Menger J, Thiele H, Friedrich MG. Clinical characteristic and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. JAMA 2011;306:277–86.

[10] Silberbauer J, Hong P, Lloyd GW. Takotsubo cardiomyopathy (left ventricular ballooning syndrome) induced during dobutamine stress echocardiography. Eur J Echocardiogr 2008;9:136–8.

[11] Cherian J, Kothari S, Angelis D, Downett B, Kirkpatrick J. Atypical takotsubo cardiomyopathy: dobutamine precipitated apical ballooning with left ventricular outflow tract obstruction. Tex Heart Inst J 2008;35:73–5.

[12] Margey R, Diamond P, McCann H, Sugrue D. Dobutamine stress echo-induced apical ballooning (takotsubo) syndrome. Eur J Echocardiogr 2009;10:395–9.

[13] Mosley HJ, Manuchehey A, McEvoy C, Rigolin V. Takotsubo cardiomyopathy induced by dobutamine infusion: a new phenomenon or an old disease with a new name. Echocardiography 2010;27:E30–3.

[14] Gianni M, Dentali F, Grandi A, Sumner G, Hiralal R, Lonn E. Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J 2006;27:1523–9.

[15] Shah BN, Simpson IA, Rakhit DJ. Takotsubo (apical ballooning) syndrome in the recovery period following dobutamine stress echocardiography: a first report. Eur J Echocardiogr 2011;12:E5.

[16] Wutthiwaropas P, Wiste JA, McCully RB, Kane GC, Scott CG, Pellilla PA. Neuropsychiatric symptoms during 24 h after dobutamine-atropine stress testing: a prospective study in 1006 patients. J Am Soc Echocardiogr 2011;24:367–73.

Atsushi Takagi (MD, FJCC) *
Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo
162-8666, Japan

Tsutomu Takagi (MD, FJCC)
Takagi Cardiology Clinic, Kyoto, Japan

Kotaro Arai (MD)
Kyomi Ashihara (MD)
Nobuhisa Hagiwara (MD, FJCC)
Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo
162-8666, Japan

* Corresponding author.
Tel.: +81 3 3353 8111 x23111; fax: +81 3 3356 0441.
E-mail address: mtakagi@hij.twmu.ac.jp (A. Takagi)

30 April 2012